TrialsgrambetaRCTs are beautiful

Cardiogenic shock & MCS

Revascularisation strategy, IABP, VA-ECMO and Impella in cardiogenic shock.

  • 2023ECMO-CS⁠Mechanical supportIn 117 patients with rapidly deteriorating cardiogenic shock, immediate VA-ECMO did not change 30-day composite of death or escalation versus early-conservative strategy.HR 0.7295% CI 0.46-1.12Read →
  • 2023ECLS-SHOCK⁠Mechanical supportIn 420 patients with acute MI complicated by cardiogenic shock, VA-ECMO did not reduce 30-day mortality versus standard care, with more bleeding and vascular complications.RR 0.9895% CI 0.80-1.19Read →
  • 2021DOREMI⁠InotropesIn 192 patients with cardiogenic shock, milrinone produced similar rates of death and major complications compared with dobutamine.Read →
  • 2017CULPRIT-SHOCK Core⁠RevascularisationIn 706 patients with multivessel disease and cardiogenic shock, culprit-only PCI with staged completion reduced 30-day death or RRT compared with immediate multivessel PCI.RR 0.83Read →
  • 2012IABP-SHOCK II Core⁠Mechanical supportIn 600 patients with MI-related cardiogenic shock undergoing revascularisation, intra-aortic balloon counterpulsation did not reduce 30-day mortality versus no IABP.RR 0.96Read →
  • 1999SHOCK Core⁠RevascularisationIn 302 patients with myocardial-infarction cardiogenic shock, early revascularisation did not reduce 30-day mortality versus initial medical stabilisation, but improved 6-month survival.46.7% vs 56.0%Read →